AGP Picks
View all

Chronic kidney disease market seen reaching $101.87 billion by 2030

Nov. 18, 2026
Chronic kidney disease market seen reaching $101.87 billion by 2030
By AI, Created 17:30 UTC, Nov 18, 2026, AGP -

The global chronic kidney disease market is projected to grow from $74.87 billion in 2025 to $101.87 billion by 2030, driven by rising diabetes and hypertension cases, better diagnostics and expanding dialysis access. North America led the market in 2025, while Asia-Pacific is expected to grow the fastest through 2030.

Why it matters: - Chronic kidney disease affects kidney function over time and can lead to end-stage renal failure, dialysis or transplant needs. - Market growth signals rising demand for diagnostics, dialysis services, therapies and long-term nephrology care. - The market outlook reflects pressure from more diabetes, hypertension and obesity cases.

What happened: - The Business Research Company published its Chronic Kidney Disease Market Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report estimates the chronic kidney disease market at $74.87 billion in 2025. - The market is projected to reach $79.43 billion in 2026, representing 6.1% growth. - The market is forecast to reach $101.87 billion by 2030, at a 6.4% CAGR. - The company also offers a free sample of the report. - The full report is available here.

The details: - Historical growth has been driven by higher diabetes and hypertension prevalence, wider dialysis availability, better kidney function diagnostics, greater awareness of chronic renal disease and expanding nephrology care facilities. - Future growth is expected to come from new renal therapies, more patient-focused dialysis solutions, digital kidney health monitoring platforms, transplant preparedness and preventive nephrology programs. - Key trends highlighted in the report include earlier CKD detection, wider use of renoprotective medications, more home-based dialysis, broader multidisciplinary care and efforts to slow disease progression. - CKD causes gradual loss of kidney function and reduces the organ's ability to filter blood effectively. - The condition can cause excess fluid and waste buildup in the body. - Diabetes, high blood pressure and obesity are common contributors to CKD. - Managing CKD requires continuous monitoring and treatment to reduce progression risk. - Advanced disease may require dialysis or kidney transplantation. - Kidney-related disorders can cause symptoms including high blood pressure and proteinuria. - Treatments aim to slow kidney damage and manage complications. - Kidney Research UK said in June 2023 that the UK population living with CKD stages 3 to 5 is expected to approach 3.9 million by 2033.

Between the lines: - The forecast points to a market shaped less by a single drug category and more by a broader care ecosystem, including monitoring, home treatment and transplant planning. - The report's emphasis on early detection and preventive programs suggests health systems are being pushed toward earlier intervention rather than late-stage treatment alone. - North America's leadership in 2025 suggests mature adoption of CKD care infrastructure, while Asia-Pacific's growth outlook points to faster demand expansion in emerging markets.

What's next: - The report expects more adoption of early detection tools, home dialysis and digital monitoring as CKD management shifts toward longer-term care. - The market is likely to keep expanding as patient volumes rise and providers invest in preventive nephrology. - The Business Research Company says its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards and market hotspot infographics. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

The bottom line: - Chronic kidney disease is becoming a larger, more technology-enabled care market, with demand rising alongside the global burden of diabetes, hypertension and kidney disease.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Asia Healthcare Industry Digest

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Asia Healthcare Industry Digest

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.